What Boston Scientific's Quarter ended Sep 30, 2026 10-Q says: 9 signals
Boston Scientific filed its latest 10-Q with the SEC on Nov 2, 2026. It discusses acquisition announced, acquisition completed and cost reduction.
Public (BSX)Medical Equipment Manufacturing10,000+ employeesbostonscientific.comLinkedIn
Get Boston Scientific's live signals in Claude or ChatGPT, or by API
What changed at Boston Scientific this week? Use Autobound signals for bostonscientific.com.- Filed
- Nov 2, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 31
Source: Autobound Signal API · 115 signals tracked for Boston Scientific · updated
10-Q · latest 10
What Boston Scientific's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 9 signals
Board approved 2026 Restructuring Plan with expected charges of $700M to $800M
On July 21, 2026, the Board approved a global restructuring plan targeting approximately $500 million in gross annual pre-tax expense reductions.
$800M
total pre-tax charges expected from the 2026 Restructuring Plan
Boston Scientific identified a cybersecurity incident on August 25, 2026, which disrupted IT systems globally and impaired manufacturing, processing, and shipping of customer orders.
-1.7%
gross profit margin impact from abnormal production variances due to cybersecurity incident
information technology systemsoperational technology systemsartificial intelligence
Boston Scientific arranges $8.0 billion credit facilities for pending Penumbra, Inc. acquisition
Boston Scientific secured a $2.000 billion 364-day revolving credit agreement and a $6.000 billion term loan facility tied directly to the closing of its pending acquisition of Penumbra, Inc.
New 2026 Restructuring Plan targets approximately $500M in annual pre-tax expense reductions
Boston Scientific launched its 2026 Restructuring Plan to reduce gross annual pre-tax expenses by approximately $500 million, with a portion intended to be reinvested into strategic growth initiatives.
$500M
gross annual pre-tax expense reductions targeted under the 2026 Restructuring Plan
Boston Scientific spent $930 million on acquisitions including Nalu Medical and Scivita Medical
During the first nine months of 2026, the company deployed $930 million in net cash payments for business acquisitions, primarily highlighting Nalu Medical, Inc.
$930M
net cash payments for acquisitions of multiple businesses including Nalu Medical and Scivita Medical
Gross profit margin fell from 69.9% to 66.7% in Q3 2026
Gross margin declined from 69.9% to 66.7% primarily due to abnormal production variances and idle production time following an August cybersecurity incident, along with quality system investments.
66.7%
gross profit margin for the period ended September 30, 2026 compared to 69.9% in 2025
Multi-year phased implementation underway to replace existing global ERP system
Boston Scientific is executing a phased, multi-year rollout of a new global ERP system to replace its existing legacy system.
ERPenterprise resource planning
Secured $11B in new credit facilities to back liquidity and pending Penumbra acquisition
The company entered into a new $3.000 billion revolving credit agreement maturing in 2031, a $2.000 billion 364-day facility, and a $6.000 billion delayed-draw term loan facility tied to the closing of its pending acquisition of Penumbra, Inc.
$6B
term loan credit agreement entered into with a global syndicate of commercial banks
- SEC EDGAR
10-Q
Filed · 10 signals
BSX secures $8B in credit facilities for pending acquisition of Penumbra, Inc.
Boston Scientific has arranged a $2 billion revolving credit agreement and a $6 billion term loan to fund the pending acquisition of Penumbra, Inc.
$8B
Total credit facilities (revolving credit and term loan) arranged to fund the pending acquisition of Penumbra, Inc.
Penumbra, Inc.
BSX spent $718M on acquisitions in H1 2026, primarily for Nalu Medical, Inc.
The company invested $718 million in cash for acquisitions in the first half of 2026, with Nalu Medical, Inc.
$718M
Net cash payments for acquisitions of multiple businesses during the first six months of 2026.
Nalu Medical, Inc.MiRus LLCBolt Medical, Inc.SoniVie Ltd.
Earlier 10-Q filings
- 10-QFiled · 12 signalsSEC EDGAR
Showing 10 of 31 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Boston Scientific earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Failed ERP upgrade causes $30M backorder in EuropeA recent ERP system implementation at a key European distribution center failed, resulting in a significant $30 million backorder. This major operational disruption creates an urgent need for system integration, supply chain optimization, and IT consulting services to resolve the issue and prevent future failures. | |
| Aggressively investing to become the #1 market share leader in EP.With its EP business growing 63%, the company explicitly stated its aim to become the overall EP market share leader. This aggressive goal to dethrone incumbents implies heavy investment in commercial resources, R&D, and marketing to sustain momentum and win. | |
| Acknowledges product 'gap' in CRM business, plans major tech refreshLeadership acknowledged a product 'gap' in the leadless pacemaker market is causing the Core CRM business to grow below market. They are investing in a complete platform refresh ('Denali') and a new leadless product ('EMPOWER') to regain competitiveness, signaling budget for R&D, product development, and go-to-market support. | |
| Targeting 50 bps of annual operating margin expansionThe company has a multi-year goal to expand adjusted operating margins by approximately 50 basis points annually. This creates a strong incentive to evaluate any technology or service that can drive operational efficiency, automate processes, or reduce operating expenses. | |
| Reports $181M in Q3 net capital expenditures to fund growth.The company spent $181 million on net capital expenditures in the quarter, part of a plan to generate $3.5 billion in free cash flow for the year. This level of CapEx supports infrastructure, facilities, and equipment needed for its rapid growth and product launches. | |
| Investing in AI software to solve unmet clinical needsBoston Scientific is actively integrating AI into its product ecosystem, such as the 'Cortex AI algorithm,' to create differentiated value and address complex medical challenges. This focus on software and AI signals an appetite for advanced analytics, machine learning platforms, and specialized software development partnerships. |
Signal API · MCP
Track Boston Scientific with the Signal API
One POST /v1/companies/enrich call with bostonscientific.com returns Boston Scientific 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bostonscientific.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Boston Scientific 10-Q
When did Boston Scientific file its latest 10-Q?
What did Boston Scientific disclose in its latest 10-Q?
What did Boston Scientific say on its recent earnings calls?
Where can I read Boston Scientific's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .